Refine
Has Fulltext
- yes (5)
Is part of the Bibliography
- yes (5)
Year of publication
- 2018 (5) (remove)
Document Type
- Journal article (3)
- Doctoral Thesis (2)
Language
- English (5)
Keywords
- Model (5) (remove)
Institute
Sonstige beteiligte Institutionen
Chronic Obstructive Pulmonary Disease (COPD) exacerbations are a considerable reason for increased morbidity and mortality in patients. Infections with influenza virus (H1N1), respiratory syncytial virus (RSV) or nontypeable Haemophilus influenzae (NTHi) are important triggers of exacerbations. To date, no treatments are available which can stop the progression of COPD. Novel approaches are urgently needed. Pre-clinical models of the disease are crucial for the development of novel therapeutic options.
In order to establish pre-clinical models which mimic aspects of human COPD exacerbations, mice were exposed to cigarette smoke (CS) and additionally infected with H1N1, RSV and/or NTHi. Clinically relevant treatments such as the corticosteroids Fluticasone propionate and Dexamethasone, the phosphodiesterase-4 (PDE-4) inhibitor Roflumilast and the long-acting muscarinic receptor antagonist Tiotropium were tested in the established models. Furthermore, a novel treatment approach using antibodies (Abs) directed against IL-1α, IL-1β or IL-1R1 was examined in the established CS/H1N1 model. Levels of IFN-γ, IL-1β, IL-2, IL-6, KC, TNF-α, RANTES, IL-17, MCP-1, MIP 1α and MIP-1β were measured in lung homogenate. Numbers of total cells, neutrophils and macrophages were assessed in bronchoalveolar lavage (BAL) fluid. Hematoxylin- and eosin- (H&E-) stained lung slices were analyzed to detect pathological changes. Quantitative polymerase-chain-reaction (qPCR) was used to investigate gene expression of ICAM-1 and MUC5 A/C. The viral/bacterial load was investigated in lung homogenate or BAL fluid. In addition to the in vivo studies, the effects of the above mentioned treatments were investigated in vitro in H1N1, RSV or NTHi-infected (primary) human bronchial epithelial cells using submerged or air-liquid-interface (ALI) cell culture systems.
Four pre-clinical models (CS/H1N1, CS/RSV, CS/NTHi, CS/H1N1/NTHi) were established depicting clinically relevant aspects of COPD exacerbations such as increased inflammatory cells and cytokines in the airways and impaired lung function.
In the CS/H1N1 model, Tiotropium improved lung function and was superior in reducing inflammation in comparison to Fluticasone or Roflumilast. Moreover, Fluticasone increased the loss of body-weight, levels of IL-6, KC and TNF-α and worsened lung function. In CS/RSV-exposed mice Tiotropium but not Fluticasone or Roflumilast treatment reduced neutrophil numbers and IL-6 and TNF α levels in the lung. The viral load of H1N1 and RSV was significantly elevated in CS/virus-exposed mice and NCI-H292 cells after Fluticasone and Dexamethasone treatment. The results from these studies demonstrate that Tiotropium has anti-inflammatory effects on CS/virus-induced inflammation and might help to explain the observed reduction of exacerbation rates in Tiotropium-treated COPD patients. Furthermore, the findings from this work indicate that treatment with Fluticasone or Dexamethasone might not be beneficial to reduce inflammation in the airways of COPD patients and supports clinical studies that link treatment with corticosteroids to an increased risk for pneumonia.
Testing of anti-IL-1α, anti-IL-1β or anti-IL-1R1 Abs in the CS/H1N1 model suggests that, in line with clinical data, antagonization of IL-1β is not sufficient to reduce pulmonary inflammation and indicates a predominant role of IL-1α in CS/virus-induced airway inflammation. In line with the in vivo findings, anti-IL-1α but not anti-IL-1β Abs reduced levels of TNF-α and IL-6 in H1N1-infected primary human bronchial epithelial ALI cell culture. Blocking the IL-1R1 provided significant inhibitory effects on inflammatory cells in vivo but was inferior compared to inhibiting both its soluble ligands IL-1α and IL-1β. Concomitant usage of Abs against IL-1α/IL-1β revealed strong effects and reduced total cells, neutrophils and macrophages. Additionally, levels of KC, IL-6, TNF-α, MCP-1, MIP-1α and MIP-1β were significantly reduced and ICAM-1 mRNA expression was attenuated. These results suggest that combined inhibition of IL-1α/IL-1β might be beneficial to reduce inflammation and exacerbations in COPD patients. Moreover, combined targeting of both IL-1α/IL-1β might be more efficient compared to inhibition of the IL-1R1.
As in the CS/virus models, corticosteroid treatment failed to reduce inflammatory cells in the CS/NTHi and CS/H1N1/NTHi models, increased the loss of body-weight and the bacterial load. Furthermore, Roflumilast administration had no significant effects on cell counts or cytokines. However, it improved compliance in the CS/NTHi model. Treatment with Azithromycin reduced the bacterial load in the CS/NTHi model and reduced numbers of total cells, neutrophils, macrophages and levels of KC and TNF-α in the CS/H1N1/NTHi model.
In conclusion, the established CS/H1N1, CS/RSV, CS/NTHi, CS/H1N1/NTHi models depict clinically relevant aspects of human COPD exacerbations in mice and provide the opportunity to investigate underlying disease mechanisms and to test novel therapies.
Kritische Knochendefekte stellen heutzutage ein ungelöstes Problem in der klinischen Praxis dar, da die verfügbaren prothetischen Optionen oft die mechanische Anpassung an das Gewebe nicht gewährleisten oder zu wichtigen immunologischen und Implantat-bedingten Komplikationen führen.
In diesem Kontext ermöglichen Tissue Engineering-Ansätze neue Strategien, um in vitro Zell-Material Interaktionen zu untersuchen und so die Implantatmaterialien zu optimieren.
In dieser Arbeit habe ich Zell-Material Interaktionen eines neuen Kollagen-basierten Scaffolds untersucht, das langfristig als Trägerstruktur für eine zellbasierte Therapie für kritische Knochendefekte entwickelt werden soll. Im Rahmen der Dissertation konnte ich belegen, dass die Kollagen-basierten makroporöse Mikrocarrier für die Zellvermehrung humaner mesenchymaler Stammzellen (MSC) und deren osteogene Differenzierung unter GMP Bedingungen verwendet werden können. Außerdem habe ich die die Kokultur von hämatopoietischen Stammzellen des Knochenmarks und multiplen Myelomzellen funktionell charakterisiert. Ich konnte erstmals Kulturbedingungen etablieren, die die Langzeitkultur ohne die Verwendung von Zytokinen ermöglicht. Mittels dieser Kokultur konnte ich ein Knochenmarknischen-Modell etablieren und die Untersuchung der Expression von zentralen Signalkaskaden der Homöostase dieser Nische untersuchen. Ich konnte die Expression von zwei verschiedenen Isoformen von Osteopontin nachweisen, die in Tiermodellen nicht gefunden werden. Diese Isoformen des Osteopontins habe ich kloniert und die rekombinanten Isoformen exprimiert und ihre Rollen in der Homöostase der Knochenmarknische untersucht.
Critical size bone defects represent nowadays an unresolved problem in the clinical practice, where the available prosthetic options often lack adequate mechanical matching to the host tissue or lead to important immunological and implant-related complications.
In this context, Tissue Engineering approaches promise more effective strategies to study cell-material interactions in vitro and consequently optimize implant materials.
In this work, I investigated the cell-scaffold interactions of a new collagen-based scaffold for a putative cell-based therapy for critical size defects to be developed. In the context of this thesis, I could demonstrate that the collagen-based macroporous microcarriers could be employed for the expansion and osteogenic differentiation of human mesenchymal stromal cells (MSCs) under GMP-compliant conditions. Moreover, I functionally characterized the co-culture of bone marrow hematopoietic stem cells and multiple myeloma cells. I was for the first time able to establish culture conditions allowing their long-term culture in absence of externally supplemented cytokines. Using this co-culture, I was able to establish a bone marrow niche model to investigate the expression of key signaling pathways involved in the niche´s homeostasis. I was able to demonstrate the expression of two different isoforms of Osteopontin, that could not previously be detected in animal models. Finally, I cloned these Osteopontin isoforms, expressed recombinant versions of the isoforms, and investigated their roles in the homeostasis of the bone marrow niche.
The results of a search for the direct pair production of top squarks, the supersymmetric partner of the top quark, in final states with one isolated electron or muon, several energetic jets, and missing transverse momentum are reported. The analysis also targets spin-0 mediator models, where the mediator decays into a pair of dark-matter particles and is produced in association with a pair of top quarks. The search uses data from proton-proton collisions delivered by the Large Hadron Collider in 2015 and 2016 at a centre-of-mass energy of root s = 13TeV and recorded by the ATLAS detector, corresponding to an integrated luminosity of 36 fb(-1). A wide range of signal scenarios with different mass-splittings between the top squark, the lightest neutralino and possible intermediate supersymmetric particles are considered, including cases where the W bosons or the top quarks produced in the decay chain are off-shell. No significant excess over the Standard Model prediction is observed. The null results are used to set exclusion limits at 95% confidence level in several supersymmetry benchmark models. For pair-produced top-squarks decaying into top quarks, top-squark masses up to 940 GeV are excluded. Stringent exclusion limits are also derived for all other considered top-squark decay scenarios. For the spin-0 mediator models, upper limits are set on the visible cross-section.
A search is presented for photonic signatures, motivated by generalized models of gauge-mediated supersymmetry breaking. This search makes use of proton-proton collision data at root s = 13 TeV corresponding to an integrated luminosity of 36.1 fb(-1) recorded by the ATLAS detector at the LHC, and it explores models dominated by both strong and electroweak production of supersymmetric partner states. Experimental signatures incorporating an isolated photon and significant missing transverse momentum are explored. These signatures include events with an additional photon or additional jet activity not associated with any specific underlying quark flavor. No significant excess of events is observed above the Standard Model prediction, and 95% confidence-level upper limits of between 0.083 and 0.32 fb are set on the visible cross section of contributions from physics beyond the Standard Model. These results are interpreted in terms of lower limits on the masses of gluinos, squarks, and gauginos in the context of generalized models of gauge-mediated supersymmetry, which reach as high as 2.3 TeV for strongly produced and 1.3 TeV for weakly produced supersymmetric partner pairs.
Properties of the Higgs boson are measured in the two-photon final state using 36.1 fb(-1) of proton-proton collision data recorded at root s = 13 TeV by the ATLAS experiment at the Large Hadron Collider. Cross-section measurements for the production of a Higgs boson through gluon-gluon fusion, vector-boson fusion, and in association with a vector boson or a top-quark pair are reported. The signal strength, defined as the ratio of the observed to the expected signal yield, is measured for each of these production processes as well as inclusively. The global signal strength measurement of 0.99 +/- 0.14 improves on the precision of the ATLAS measurement at root s = 7 and 8 TeV by a factor of two. Measurements of gluon-gluon fusion and vector-boson fusion productions yield signal strengths compatible with the Standard Model prediction. Measurements of simplified template cross sections, designed to quantify the different Higgs boson production processes in specific regions of phase space, are reported. The cross section for the production of the Higgs boson decaying to two isolated photons in a fiducial region closely matching the experimental selection of the photons is measured to be 55 +/- 10 fb, which is in good agreement with the Standard Model prediction of 64 +/- 2 fb. Furthermore, cross sections in fiducial regions enriched in Higgs boson production in vector-boson fusion or in association with large missing transverse momentum, leptons or top-quark pairs are reported. Differential and double-differential measurements are performed for several variables related to the diphoton kinematics as well as the kinematics and multiplicity of the jets produced in association with a Higgs boson. These differential cross sections are sensitive to higher order QCD corrections and properties of the Higgs boson, such as its spin and CP quantum numbers. No significant deviations from a wide array of Standard Model predictions are observed. Finally, the strength and tensor structure of the Higgs boson interactions are investigated using an effective Lagrangian, which introduces additional CP-even and CP-odd interactions. No significant new physics contributions are observed.